Key Takeaways Illumina will develop KRAS-based companion diagnostics with global pharma partners.ILMN's TSO Comprehensive generates tumor profiles to guide targeted therapy selection.New CDx partnerships expand ILMN's pipeline supporting precision oncology care.Illumina, Inc. (ILMN)  is set to partner with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight Oncology (“TSO”) Comprehensive genomic profiling test. The new CDx partnerships will focus on KRAS al ...

Company Overview - Thermo Fisher Scientific (TMO) launched the Olink Target 48 Neurodegeneration panel, a targeted proteomics immunoassay designed to enhance neurodegenerative disease research by measuring 41 key proteins with absolute quantification from as little as 1µL of plasma sample [1][5][8] - The new panel is part of Olink's expanding portfolio of multiplex disease panels, emphasizing the company's commitment to advancing precision medicine and neurology research [2][3] Product Details - The Target 48 Neurodegeneration panel is designed to meet the increasing demand for scalable and reproducible protein measurements in the context of rising neurodegenerative diseases such as Alzheimer's and Parkinson's [5][9] - It is compatible with the Olink Signature Q100 benchtop system, facilitating a simplified workflow and minimal maintenance, which accelerates biomarker research [6][8] Market Insights - The neurodegenerative disease diagnostics market is projected to grow from $4.70 billion in 2025 at a compound annual growth rate of 7.5% through 2030, driven by the increasing prevalence of neurodegenerative disorders and advancements in diagnostic technologies [10] Financial Performance - Thermo Fisher has a market capitalization of $181.05 billion and an earnings yield of 4.7%, significantly higher than the industry's -4.2% yield [4] - Over the past three months, TMO shares have increased by 21.6%, outperforming the industry growth of 1.9% [12]